
1. Technology overview
Quibim, S.L. is a medical imaging AI company headquartered in Valencia, Spain, with offices in Madrid, Barcelona, New York and Cambridge (UK). It turns medical images into quantitative biomarkers to support radiologists and drug development teams.
Its cloud-based, tissue-agnostic platform includes QP-Prostate (prostate MRI reading support), QP-Brain (brain volumetry and white matter hyperintensity), QP-Liver (fat and iron quantification), QP-Breast and QP-Insights, a platform for imaging data management and radiomics analysis. Biopharma partners use it in clinical studies, and hospitals integrate it with PACS.
2. Highlighted features & specifications
- QP-Prostate: prostate MRI reading support compliant with PI-RADS.
- QP-Brain: brain volumetry and white matter hyperintensity analysis.
- QP-Liver: liver fat and iron quantification with liver segmentation.
- QP-Breast: CE and UKCA-marked AI for breast cancer detection on MRI, launched July 2026.
- QP-Insights: imaging data management and radiomics analysis linked to EHR and multi-omics data.
3. Potential application
Large Vietnamese hospitals could use QP-Prostate and QP-Breast as reading support in MRI-based cancer diagnosis. Pharma companies and clinical research organizations running trials in the region could use QP-Insights for imaging biomarker analysis.
4. Benefits
Provides quantitative imaging biomarkers instead of purely visual reads. QP-Prostate supports PI-RADS compliant reading, and the platform integrates with PACS and EHR data. Security is covered by ISO 27001:2022 certification with HIPAA and GDPR compliance. The newest module, QP-Breast, carries CE and UKCA marking.
5. Market trends & opportunities
Cancer screening and treatment planning increasingly rely on MRI, which raises demand for quantitative AI reads and standardized reporting. Vietnamese cancer and imaging centers adopting MRI for prostate and breast diagnosis can use such tools to support radiologists with limited subspecialty capacity.
6. Other information
Quibim, S.L., registered in Valencia, Spain, with offices in Madrid, Barcelona, New York and Cambridge (UK). 2026 news: Health Canada licence for QP-Prostate (June), CE and UKCA-marked QP-Breast launch (July), selection for a New York strategic AI program (May). ISO 27001:2022.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































